Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Oct;40(10):2428–2430. doi: 10.1128/aac.40.10.2428

In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis.

L Mulazimoglu 1, S D Drenning 1, V L Yu 1
PMCID: PMC163549  PMID: 8891159

Abstract

Two oxazolidinones (U100592 and U100766), trovafloxacin, and a streptogramin combination (dalfopristin-quinupristin) were highly active in vitro against Staphylococcus aureus and Staphylococcus epidermidis, including methicillin-resistant strains. Trovafloxacin was more active than ciprofloxacin. Time-kill synergy studies demonstrated indifference for the oxazolidinones combined with vancomycin and rifampin against methicillin-resistant staphylococci. Spontaneous resistance was observed with all agents.

Full Text

The Full Text of this article is available as a PDF (178.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Collins L. A., Malanoski G. J., Eliopoulos G. M., Wennersten C. B., Ferraro M. J., Moellering R. C., Jr In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother. 1993 Mar;37(3):598–601. doi: 10.1128/aac.37.3.598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Daly J. S., Eliopoulos G. M., Reiszner E., Moellering R. C., Jr Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J Antimicrob Chemother. 1988 Jun;21(6):721–730. doi: 10.1093/jac/21.6.721. [DOI] [PubMed] [Google Scholar]
  3. Hirschhorn L., Neu H. C. Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620. Antimicrob Agents Chemother. 1986 Jul;30(1):143–146. doi: 10.1128/aac.30.1.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Levine D. P., Cushing R. D., Jui J., Brown W. J. Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med. 1982 Sep;97(3):330–338. doi: 10.7326/0003-4819-97-3-330. [DOI] [PubMed] [Google Scholar]
  5. Neu H. C., Chin N. X. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother. 1994 Nov;38(11):2615–2622. doi: 10.1128/aac.38.11.2615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Zurenko G. E., Yagi B. H., Schaadt R. D., Allison J. W., Kilburn J. O., Glickman S. E., Hutchinson D. K., Barbachyn M. R., Brickner S. J. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother. 1996 Apr;40(4):839–845. doi: 10.1128/aac.40.4.839. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES